Roche Molecular Systems, Inc.

Roche Diagnostics Gmbh

F. Hoffmann-la Roche Ag

Yu Chuan Tai

Wei-min Liu

Yan Li

Nancy J Schoenbrunner

Rajiv Dua

Christopher David Santini

Marcel Fontecha

Lori Steiner

Chih-Jian Lih

Nancy Schoenbrunner

Christopher Santini

Wei-Min Liu

Techniques are provided for determining settings of a dPCR experiment for the detection of a chromosomal aneuploidy in a plasma sample from a female pregnant with a fetus. Data about the sample, the dPCR process, and a desired accuracy can be used to determine the settings. Such settings can include a minimal input number of control chromosome molecules for the dPCR experiment, a minimal number of control chromosome molecules for a pre-amplification procedure, and a number of PCR cycles in the pre-amplification procedure. These settings can be used to satisfy the accuracy specified by the accuracy data. Thus, the dPCR experiment can be designed to achieve the desired accuracy while reducing cost, e.g., by not using more of a sample than needed and not performing more pre-amplification than needed or performing more manipulations than needed.

Digital PCR for non-invasive prenatal testing

Provided herein are methods and compositions to classify DLBCL subtypes using quantitative RT-PCR.

Methods and compositions for classifying DLBCL

This invention provides methods, compositions, and kits relating to biomarkers whose expression levels are correlated with diffuse large B-cell lymphoma (DLCBL) patients' response to treatment with a CD20 antagonist, such as a CD20 antibody, exemplified by rituximab. The methods, compositions, and kits of the invention can be used to identify DLBCL patients who are likely or not likely, to respond to anti-CD20 treatments.

Predicting response to anti-CD20 therapy in DLBCL patients

Growing community of inventors

Pleasanton, CA, United States of America

Yu Chuan Tai